Overview

Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.